Drugs / QL2401
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07331545 | Jan → Jul 2026 overdue | metabolic dysfunction-associated steatohepatitis | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07620366 | Jun 2026 → Jun 2027 expected | metabolic dysfunction-associated steatohepatitis | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL2401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07620366 ↗ |
| Modality | Protein / enzyme biologic | “recombinant fusion protein” NCT07331545 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT07331545 ↗ |